AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Browse creative work from home business ideas that can help you start earning. Discover the perfect fit for your skills!
18,910 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A high-stakes cash bid from Merck KGaA sent Bio-Techne stock higher and sparked a flurry of trading. Here’s what inve...
Investors chasing high-yield income need a rigorous dividend safety check: high-dividend. This story uses VYM to illu...
Celebrity moments can shape our choices—sometimes inspiring smart budgeting, other times fueling impulse buys. This a...
Investor participation in crypto funding fell to 651 in Q2 2026, the lowest since 2020, underscoring a tighter, more ...
The S&P 500 has delivered double-digit gains for years, but a new era may bring slower growth and higher costs. This ...
Micron stock just dropped as traders weigh demand for memory parts against a backdrop of cyclical pricing. This artic...
A looming NBCUniversal spin-off reshapes the media landscape as Netflix weighs a transformative deal. If talks advanc...
Former President Trump disclosed soaring digital-asset holdings, including hundreds of millions from meme-token sales...
A late-June ethics filing shows Trump’s government filing just disclosing roughly $1.4 billion in crypto earnings for...
The Nasdaq surged in the first half of 2026 as AI infrastructure names led a broad rally. Three AI stocks are showing...
The GENIUS Act's one-year rulemaking deadline lands on July 18, placing stablecoin issuers under intense regulatory s...